chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Diagnosed with shingles; Rash on her stomach; This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a 85-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles (on unknown date in 2009 experienced Shingles).   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced shingles and rash. On an unknown date, the outcome of the shingles and rash were recovered/resolved.   It was unknown if the reporter considered the shingles and rash to be related to Shingrix.  Additional deatils were provided as follows: The age vaccination was not reported. The patient was vaccinated with 1st dose of Shingrix and experienced a rash on her stomach. The patient went to the hospital (not admitted) to check it out and was diagnosed with shingles. The patient had a prior history of shingles in 2009. The patient thought the rash was poison ivy but was diagnosed with shingles. The reporter consent to follow up. This case was linked with case US2020202980 by patient link.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020202980:same reporter
raise 3-4 cm papular rash about 10 minutes after injection MMR vaccine, didn't get any larger after 30 minutes, no other symptoms
Fainted while sitting; Too much pain in hand; chills; Weakness; This is a spontaneous report from a contactable consumer (patient). A 34-year-old female patient received first dose of BNT162B2(Batch/Lot Number: Unknown), via an unspecified route of administration on 24Mar2021 18:15 at single dose in the left arm for COVID-19 immunization. Medical history included Known allergies: NSAID on an unknown date. The patient's concomitant medications were not reported. The patient previously took ibuprofen and experienced allergy. On 25Mar2021 03:00, the patient experienced fainted while sitting, too much pain in hand, chills and weakness. Therapeutic measures were taken as a result of all the events which included Tylenol. The adverse event result in doctor or other healthcare professional office/clinic visit. The patient was not pregnant at the time of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination and did not receive any other medications within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The outcome of the events was not recovered.   The following information on the lot/batch number has been requested.
threw up this morning; tried to go to work but gave out; had to get some rest because she felt dizzy; woke up last night with chills and fever; woke up last night with chills and fever; had aches and pain all over her body; not feeling good at all; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-HCP) from medical information team. The reporter is the patient. Other Case identifier(s): US-PFIZER INC-202200463386 (Pfizer).  A 57-year-old female patient received bnt162b2 (BNT162B2), administration date 20Mar2022 (Batch/Lot number: unknown) at the age of 57 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "she had moderna for her 1st and 2nd dose" (unspecified if ongoing), notes: she had Moderna for her 1st and 2nd dose. The patient's concomitant medications were not reported. Vaccination history included: Moderna (Dose: 1), for COVID-19 Immunization; Moderna (Dose: 2), for COVID-19 Immunization.  The following information was reported: CHILLS (non-serious), PYREXIA (non-serious) all with onset 20Mar2022, outcome "unknown" and all described as "woke up last night with chills and fever"; PAIN (non-serious) with onset 20Mar2022, outcome "unknown", described as "had aches and pain all over her body"; VOMITING (non-serious) with onset 21Mar2022, outcome "unknown", described as "threw up this morning"; LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (non-serious) with onset 21Mar2022, outcome "unknown", described as "tried to go to work but gave out"; DIZZINESS (non-serious) with onset 21Mar2022, outcome "unknown", described as "had to get some rest because she felt dizzy"; MALAISE (non-serious) with onset Mar2022, outcome "unknown", described as "not feeling good at all".  Additional information: Patient stated that she received the pfizer covid-19 vaccine booster dose at 3 or 4 o'clock on sunday and mentioned she had moderna for her 1st and 2nd dose. She was told by the pharmacist that it's alright to mix. She stated that she woke up last night with chills, fever and also had aches and pain all over her body and threw up this morning. She tried to go to work but gave out. She stated that she had to get some rest because she felt dizzy, and she is not feeling good at all. She also stated that she did not experience this with the first two doses. She wanted to know when the effects will wear out. The case was reported as non-serious.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Information has been received from a 45 year old female patient with diabetes, a penicillin allergy and a history  of carpal tunnel syndrome who over 5 years ago in approximately 1997, was vaccinated with a dose of pneumococcal vaccine 23 polyvalent. The patient indicated the reason for vaccination was prevention of asthmatic bronchitis and peumonia. Concomitant therapy included cetrizine hydrocholoride (Zyrtec),lisinopril (Zestril), atorvastatin calcium (Lipitor), pentoxifylline (Trental ), glyburide and metformin hydrocholride (Glucovance), amitriptyline hydrochloride, diltiazem hydrochloride and furosemide. On Jan 13, 2003, the patient reported that the effectiveness of the pneumococcal vaccine 23 polyvalent has worn off because she developed an asthmatic bronchitis cold within the last two weeks. Follow up information was received from a physician stating that the patient received the pneumococcal vaccine 23 polyvalent about  5 years ago with no adverse events. The patient presented to the clinic requesting a booster. The physician noted that the patient had no medical indication for a booster. The patient was upset that she was getting a lot of colds this winter and felt that was an indication her pneumococcal vaccine 23 polyvalent had worn off. The patient has had no documented pneumonia or pneumococcal infection this year. The physician stated"I do not know how to call this vaccine adverse event....I feel the patient is having no symptoms or problems related to her original (pneumococcal vaccine 23 polyvalent. Additional information is not expected.
After 24 hours of administering the Modern Booster vaccine .25 ml IM in the left deltoid, the patient presents hives in the neck area, and the left shoulder and chest, edema and a small ball under the left armpit. He does not present shortness of breath at the moment.
Cold chills, migraine, lightheaded,  stomach cramping,  back pain, body aches
FULL BODY RASH AND ITCHING, SWOLLEN LIPS, EARS AND EYES
Menstrual cramps, Nausea, cervical mucus indicating ovulation- all outside of regular cycle timeline
Although a sore arm was to be expected, the patient returned to the pharmacy months later and is still complaining of arm pain. He states that it started after the immunization and that it is in the joint. Although I don't remember the details of this immunization, I did administer it IM but he's complaining of symptoms of bursitis from inappropriate administration of an IM vaccine.
Driving home (passenger) she suffered a cardiac arrest.  Was found to have a total occlusion of her right coronary artery and an inferior ST elevation myocardial infarction and cardiogenic shock
EE tested positive for COVID > 14 days after 2nd dose of Pfizer vaccine
haven't been feeling 100% himself; he felt like his breath was leaving him; This spontaneous case was reported by a patient and describes the occurrence of FEELING ABNORMAL (haven't been feeling 100% himself) and RESPIRATION ABNORMAL (he felt like his breath was leaving him) in a 34-year-old male patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination.     Patient does not have allergies to medications, food and other products. Patient never had COVID positive test or diagnosis. No information relating to mentioned AE and both Acute and Chronic similar past. The patient not experienced similar event in the past.    On 26-Feb-2022, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 26-Mar-2022, received second dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced FEELING ABNORMAL (haven't been feeling 100% himself) and RESPIRATION ABNORMAL (he felt like his breath was leaving him). At the time of the report, FEELING ABNORMAL (haven't been feeling 100% himself) and RESPIRATION ABNORMAL (he felt like his breath was leaving him) outcome was unknown.            No concomitant medication was reported.  No treatment medication was reported.
Vaccines given 7/2/03. Petechiae/purpura started 7/12. Severe thrombocytopenia. Received platelets, 2 doses IVIG; antibody mediated thrombocytopenia resolved. Suspect Hepatitis B. D/C summary and hematology consultation confirm diagnosis of thrombocytopenia. Per review of medical record, diagnosis of antibody-mediated thrombocytopenia is confirmed. Symptoms of ecchymosis and petechiae were noted.
Patients were given non diluted Pfizer doses totaling .3 concentrated purple top Pfizer. Patients have been notified that they were given incorrect doses. Official Pfizer guidance states that patients no longer need any vaccine doses going forward, and that it is not harmful to patients. They may experience increased systemic or local reaction. Draw Lead was responsible for drawing the doses administered, and has been informed of the situation. Patients experienced no reactions within the 15 minute observation window and have been notified of incorrect dosage given to them.
Dizzy; Diaphoretic; Chest pain; Breathing heavy Narrative:   Other Relevant History:
Fever, chills, muscle aches. Severe enough to keep me up all night. Unsure of temperature. Lasted for about 16 hours
Pt recv vax on 8/15/97; 1 wk later pt exp worsened bruising & heavy menstrual bleeding.
I went to Public Health Clinic had my 3rd shot of COVID-19. I waited my 15 minutes after and I was feeling well. I went home and did my daily activity. Months later I got COVID-19. I woke up on Sunday with a headache and with a fever. Days past by and my stool is running and a different taste in my mouth. I am having more Phlegm and coughing more than usual. I spoke to my healthcare care provider and I am taking antibiotics. I am still positive.
Client reported that one week after receiving the COVID vaccine Moderna, the client developed "chills, sweating, fever, increased saliva, and a headache. My tonsils turned white, puffy, and swollen." The client stated these symptoms lasted about 10 days. The client stated he had a fever of 103 degrees Fahrenheit for about 10 days. The client denied any dizziness or shortness of breath. The client stated he went to urgent care where he was provided a prescription for Amoxicillin. The client stated the Amoxicillin did not provide relief of his symptoms. The client returned to urgent care where the client tested negative for COVID, infectious mononucleosis, and strep throat. The client stated he was diagnosed with tonsillitis. The client denies any chronic conditions. No known allergies.
Administration of vaccine past published expiry; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administration of vaccine past published expiry) in an adult female patient who received mRNA-1273 (Spikevax) (batch no. 059H21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administration of vaccine past published expiry). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administration of vaccine past published expiry) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No Concomitant information was reported. The vial was initially stored in the refrigerator on 01-Apr-2022. The vaccine were thawed on the day of administration and administration was spread out throughout  the end of March to the beginning of April. The vial did not undergone any temperature excursions.  No Treatment information was reported.
Arthritis-type pains and joint problems; swelling, loss of flexibility and pain. Occurred 4 to 6 months after last shot. Dx'd as arthritis. Got a second opinion and was dx'd as fibromyalgia and treated with prednisone. Went to another facility and was dx'd as arthritis and treated as such.
Pain in shoulder at time of injection. Visit to doctor indicated shot was in shoulder joint not deltoid muscle. Six weeks since shot am still experiencing acute pain in shoulder and bicep area. Limited range of motion of entire left arm. Tinging in left hand.
high fever, severe muscle aches and spasm, urinary accident at night, headache, severe fatigue.
received an expired 2nd dose of Moderna COVID-19 vaccine; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (received an expired 2nd dose of Moderna COVID-19 vaccine) in a 24-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Oct-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (received an expired 2nd dose of Moderna COVID-19 vaccine). On 13-Oct-2021, EXPIRED PRODUCT ADMINISTERED (received an expired 2nd dose of Moderna COVID-19 vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided by reporter. No treatment medications were reported.
Vaccine administered after more than 1 temperature excursion; Vaccine administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) in a 46-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 019B21A and 014M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 27-Feb-2021 at 1:53 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 27-Mar-2021 at 1:41 PM, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 milliliter. On an unknown date, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 46.70 years for administration date of 27-Feb-2021. The age of patient was provided as 46.77 years for administration date of 27-Mar-2021.  Concomitant products were not provided.  On 27-Feb-2021, at excursion times of 09 AM, 11 AM, 12 PM, 1 PM, 2 PM, 3 PM, 4 PM and 5 PM, temperatures were 33, 35, 35, 35, 35, 34, 34 and 35 respectively, total doses given for the day was 199, condition of vaccine prior to administration was not frozen, vaccine was moved to fridge on 24-Feb-2021, vial was moved to clinic on 27-Feb-2021. 20 vials were sent to clinic. Vaccine BUD date was 26-Mar-2021.  On 27-Mar-2021, at excursion times of 09 AM and 10 AM, temperatures were 35 and 35 respectively, total doses given for the day was 195, condition of vaccine prior to administration was not frozen, vaccine was moved to fridge on 23-Mar-2021, vial was moved to clinic on 27-Mar-2021. 20 vials were sent to clinic. Vaccine BUD date was 22-Apr-2021.   The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a Fisher brand traceable temperature monitor at every hour.  After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  It was reported that the patient was administered with vaccines that experienced more than 1 temperature excursion during 33 weeks in 2021. The HCP explained that each time a vial was put into a cooler, there was a period of 1 hour or 1 and half hour approximately, when the temperature data logger registered 34 or 35 degree F.  Treatment medications were not reported.
Information has been received from a 61 year old male pt with no known allergies who in December 2002 and on 12/04/03 at 13:20 was vaccinated in the right deltoid with a first and second dose of pneumococcal 23v polysaccharide vaccine, respectively (Lot #: second dose 646322/0530N). It was noted that the pt inquired "as to a possible overdose". There was no illness at the time of vaccination. It was noted that the "HCP'S" at the office were not aware that he received the vaccine last year. Concomitant therapy included a dose influenza vaccine in the left deltoid. Concomitant medication included Lipitor, "bisoprolol" and aspirin 81mg. On 12/05/03, he stated his "site is swollen, red and very painful" and "he cannot raise his right arm". A prescription drug was not required. There were no diagnostic lab tests performed. Unspecified medical attention was sought. It was noted initially that the pt had not recovered; however subsequent recovery status was reported as "unknown" by another reporter. There was no product quality complaint involved. Follow up information from a health care professional indicated that the pt did not contact the MD's office with any adverse reactions. "The pt requested 'Pneumovax' and after receiving it, he asked when he should get another one as he received a vaccine in 2002 also." No further information is available.
Pain and swelling at injection site, headaches, chills, body ache, pain and swelling on collarbone, left side
more than 36 days for administration of second dose; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (more than 36 days for administration of second dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 08-Apr-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (more than 36 days for administration of second dose). On 08-Apr-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (more than 36 days for administration of second dose) had resolved.            Concomitant medications were not reported  No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 21-Oct-2021: Non-significant Follow-up, contains reporter email address added.
Mandatory EUA Reporting - Received 1st Pfizer covid vaccine on 3/11/21. Admitted to hospital on 3/30/21 with covid. Observed overnight and discharged home the following day.
Initial pain and slight swelling at injection site. Discomfort lasted 3 -4 days  About 7 days after injection a very itchy rash developed on my left arm, chest, and right arm. The rash are small, prickly red spots that cover most of the area on my arms and upper chest.  It is so itchy that I broke the skin while scratching in my sleep. I googled the condition and find that my symptoms do not match most others as it is not localized at the injection site.
Pt received both doses of the COVID vaccine (on 3/5/2021 and 3/30/2021 respectively).  Pt tested positive for Covid on 10/11/2021.  She presented to the ED at that time for Covid related symptoms, including weakness resulting in several falls.  Admitted 10/11/2021 and is currently being treated for COVID.
The patient's left arm is red and has blisters at the site of injection. The patient also stated that the injection site it itching. The patient received her vaccine on Friday 9/29/2017 and symptoms began on Sunday 10/1/2017. The patient visited her physician on Monday 10/2/2017 to let her check her injection site. The patient stated that her physician said her injection may have activated her shingles. She had a case of shingles about 10 years ago.
Every two weeks I get body aches and weakness. I feel achy all over and feverish. I sometimes do have fever and sometimes I don?t.
Information has been received from nurse practitioner concerning a "high school age" female patient who on unspecified date was vaccinated with two doses of GARDASIL vaccine. It was reported that the patient fainted after receiving her second dose of GARDASIL vaccine. I was reported that the patient recovered shortly after fainting. The patient sought medical attention. This is one of several cases from the same source. Additional information has been requested.
nausea; Headache; This is a spontaneous report from a non-contactable nurse. A 43-year-old female patient received bnt162b2 (BNT162B2 also reported as COVID vaccine (brand Pfizer); lot number: 5730; expiration date: unknown), intramuscular left arm on 19Dec2020 11:00 at a single dose for covid-19 vaccination. The patient's medical history and concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. It was reported that the patient had headache about 2 hours (13:00) after vaccination then about 6 hours (17:00) after she had nausea. The reporter considered the events as non-serious which did not result to death, not life-threatening, or did not caused/prolonged hospitalization, disabling/incapacitating or congenital anomaly/birth defect. No treatment was received for the adverse events. The patient has not been tested for COVID-19 since the vaccination. The outcome of the events was recovered on an unspecified date.  No follow-up attempts are possible. No further information is expected.
Vasovagal syncope shortly after receiving hep A and Gardasil vaccine, fell, hit nose on a drawer, loss of consciousness, sent to ER in transport broke nose.
Feeling of constricted airway due to thyroid inflammation  for first week after complete vaccination and spontaneous fluttering of heart/arrhythmia/tachycardia with some shortness of breath even after 5 months after complete vaccination.